PDF(Pubmed)
Abstract：
The article discusses the importance of accurately distinguishing HER2-low from HER2-negative breast cancer, as novel ADCs have demonstrated activity in a large population of patients with HER2-low-expressing BC. While current guidelines recommend a dichotomous classification of HER2 as either positive or negative, the emergence of the HER2-low concept calls for standardization of HER2 testing in breast cancer, using currently available assays to better discriminate HER2 levels. This review covers the evolution and latest updates of the ASCO/CAP guidelines relevant to this important biomarker in breast cancer, including still-evolving concepts such as HER2 low, HER2 heterogeneity, and HER2 evolution. Our group presents the latest Mexican recommendations for HER2 status evaluation in breast cancer, considering the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, accurate HER2 status assessment remains one of the most important biomarkers in breast cancer, and the commitment of Mexican pathologists to theragnostic biomarker quality is crucial for providing the most efficient care in oncology.
摘要：
本文讨论了准确区分低HER2和HER2阴性乳腺癌的重要性，作为新型ADC已在大量HER2低表达BC患者中显示出活性。虽然目前的指南建议将HER2分为阳性或阴性，HER2低概念的出现要求乳腺癌HER2检测的标准化，使用目前可用的检测方法来更好地区分HER2水平。这篇综述涵盖了与乳腺癌这一重要生物标志物相关的ASCO/CAP指南的演变和最新更新。包括仍在发展的概念，如HER2低，HER2异质性，HER2进化我们小组提出了墨西哥对乳腺癌HER2状态评估的最新建议，考虑ASCO/CAP指南并引入低HER2概念。在个性化医疗时代，准确的HER2状态评估仍然是乳腺癌最重要的生物标志物之一，墨西哥病理学家对治疗无关生物标志物质量的承诺对于提供最有效的肿瘤学护理至关重要。
